Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma

Zhao, Guodong; Chen, Weike; Juanjuan, He; Zhao, Lihua; Zhao, Yueshu; Sun, Cuilian; Nie, Dongli; Jin, Feng; Kong, Ling‐Bin

doi:10.1016/j.wneu.2020.09.031

Cited by 12 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The binding of PD-1 to PD-L1 alters the activity of T cells through numerous mechanisms, thereby inhibiting T cell proliferation, survival, and their ensuing effects [ 25 ]. Moreover, the level of infiltration of T cells in GHPA and the expression of PD-L1 are higher compared with other PAs, which is consistent with the results of our present study [ 8 , 26 – 28 ]. We show here that the populations of CD4 + cells, CD8 + cells, and the levels of PD-L1 in GHPA were higher compared with those of NFPA, indicating a unique association of the TIME with GHPA.…”

Section: Discussionsupporting

confidence: 93%

The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor

Nie

Fang

Cheng

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

Context Pituitary adenoma (PA) is a common intracranial tumor. The evidence indicates that the tumor immune microenvironment (TIME) is associated with PA and that the intestinal flora influences other tumors' growth through interacting with the TIME. However, how the intestinal microbial flora contributes to the development of PA through the immune response is unknown. Objective and methods Here we used high-throughput Illumina MiSeq sequencing targeting the V3−V4 region of the 16S ribosomal RNA gene to investigate the intestinal flora of patients with growth hormone-secreting pituitary adenoma (GHPA), nonfunctional pituitary adenoma (NFPA), and healthy controls. We determined their effects on tumor growth and the TIME. Fecal microbiota transplantation (FMT) was performed after adoptive transfer via peripheral blood mononuclear cells to tumor-bearing nude mice, which allowed the study of the immune response. Result We discovered differences in the structures and quantities of intestinal flora between patients with GHPA, patients with NFPA, and healthy controls. After FMT, the intestinal flora of GHPA patients promoted the growth of tumors in mouse models. The number of programmed cell death ligand 1 (PD-L1)-positive cells increased in tumor tissues as well as the extent of infiltration of CD8+ cells. Increased numbers of CD3+CD8+ cells and increased levels of sPD-L1 were detected in peripheral blood. Conclusion These findings indicated that the intestinal flora of patients with GHPA promoted tumor growth and that the immune system may mediate this change.

show abstract

Section: Discussionsupporting

confidence: 93%

The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor

Nie

Fang

Cheng

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…PD-L1 is an immunosuppressive factor in tumors, and anti-PD-L1 therapy has been shown to benefit many cancer patients ( 16 , 19 , 20 ). CD8 + TILs and PD-L1 have been reported to be expressed in the TME of PAs ( 9 – 11 , 17 , 18 ). However, there are few studies evaluating the expression of these biomarkers in PAPAs.…”

Section: Discussionmentioning

confidence: 99%

PD-L1 and tumor-infiltrating CD8+ lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas

et al. 2023

View full text Add to dashboard Cite

ObjectiveTo investigate the levels of tumor-infiltrating CD8+ lymphocytes (CD8+ TILs) and the expression of programmed cell death receptor ligand 1 (PD-L1) in the tumor microenvironment (TME) of pediatric and adolescent pituitary adenomas (PAPAs) and analyze the correlation between their levels and the clinical characteristics.MethodsA series of 43 PAPAs cases were enrolled over a period of 5 years. To compare the TME of PAPAs and adult PAs, 43 PAPAs cases were matched with 60 adult PAs cases (30 cases were between 20 and 40 years old, and 30 cases were older than 40 years) for main clinical characteristics. The expression of immune markers in PAPAs was detected by immunohistochemistry, and their correlation with the clinical outcomes was analyzed using statistical methods.ResultsIn the PAPAs group, CD8+ TILs level was significantly lower (3.4 (5.7) vs. 6.1 (8.5), p = 0.001), and PD-L1 expression (0.040 (0.022) vs. 0.024 (0.024), p < 0.0001) was significantly higher as compared with the older group. The level of CD8+ TILs was negatively correlated with the expression of PD-L1 (r = −0.312, p = 0.042). Moreover, CD8+ TILs and PD-L1 levels were associated with Hardy (CD8, p = 0.014; PD-L1, p = 0.018) and Knosp (CD8, p = 0.02; PD-L1, p = 0.017) classification. CD8+ TILs level was associated with high-risk adenomas (p = 0.015), and it was associated with the recurrence of PAPAs (HR = 0.047, 95% CI 0.003–0.632, p = 0.021).ConclusionCompared with the TME in adult PAs, the TME in PAPAs was found to express a significantly altered level of CD8+ TILs and PD-L1. In PAPAs, CD8+ TILs and PD-L1 levels were associated with clinical characteristics.

show abstract

“…Several studies have described the expression of PD-L1 in pituitary neuroendocrine tumors (PitNETs). In general, the present studies indicated that PD-L1 is highly expressed in invasive pituitary tumors as well as in some functional pituitary tumors, particularly in somatotrophs and lactotrophs [ 28 – 33 ]. Furthermore, in a recent study of 264 pituitary adenoma specimens, researchers found a high incidence of significant overexpression of PD-L1 in Pit-1-positive tumors [ 34 ].…”

Section: Pd-1/pd-l1mentioning

confidence: 75%

Immune Checkpoints: Therapeutic Targets for Pituitary Tumors

et al. 2021

View full text Add to dashboard Cite

Pituitary tumors are the third most common intracranial tumors in adults. Treatment of refractory pituitary tumors is known to be difficult due to limited treatment options. As a promising therapeutic method, tumor immunotherapy has been applied in the treatment of many tumors, including pituitary tumors. Immune checkpoint blocking is one of the effective strategies to activate antitumor immunity. Immune checkpoints prevent tissue damage by regulating the immune response of peripheral tissues and participate in the maintenance of a normal immune environment. In the presence of a tumor, inhibition of T cell activity by tumor cells binding to immune checkpoints and their ligands is an important mechanism for tumor cells to escape immune injury. In this review, we summarize the latest findings of immune checkpoints and their potential as immunotherapeutic targets for pituitary tumors.

show abstract

Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma

Cited by 12 publications

References 28 publications

The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor

The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor

PD-L1 and tumor-infiltrating CD8+ lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas

Immune Checkpoints: Therapeutic Targets for Pituitary Tumors

Contact Info

Product

Resources

About